Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast Cancer.

Cancers (Basel) · 2023 · PMC10527344 · PMID 37760527

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

While MONALESSA-2 [ 5 ] has demonstrated a significant overall survival (OS) benefit with the addition of the CDK4/6-inhibitor ribociclib to letrozole and MONARCH-3 [ 6 ] showed a strong trend towards OS significance with the addition of abemaciclib to endocrine therapy in its interim analysis, PALOMA-2 [ 7 ] did not demonstrate similar statistical improvement in OS with the addition of palbociclib to letrozole.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.